摘要
目的探讨康莱特注射液联合GP化疗方案对非小细胞肺癌(NSCLC)患者血管内皮生长因子(VEGF)及生存质量的影响。方法选择赣州市肿瘤医院2019年8月至2021年8月收治的80例NSCLC患者,根据单盲抽法将其分为两组,各40例。对照组采用GP化疗方案,观察组在对照组基础上,采用康莱特注射液治疗,比较两组治疗前、治疗2个月后VEGF水平、生存质量[癌症生命质量核心量表(QLQ-C30)]。结果治疗2个月后,两组VEGF水平低于治疗前,且观察组低于对照组(P<0.05);治疗2个月后角色、躯体、认知、社会、情绪评分均高于治疗前,且观察组各评分高于对照组(P<0.05)。结论康莱特注射液联合GP化疗方案治疗可有效降低NSCLC患者VEGF水平,提高患者生存质量。
Objective To investigate the effect of kanglaite injection combined with GP chemotherapy regimen on vascular endothelial growth factor (VEGF) and quality of life in patients with non-small cell lung cancer (NSCLC). Methods A total of 80 NSCLC patients admitted to Ganzhou Cancer Hospital from August 2019 to August 2021 were selected and divided into two groups according to the blind drawing method, with 40 cases in each group. The control group was treated with GP chemotherapy, and the observation group was treated with kanglaite injection on the basis of the control group. The levels of VEGF and quality of life were compared between the two groups before treatment and after two months of treatment [Cancer Quality of Life Core Scale (QLQ-C30)]. Results After two months of treatment, the levels of VEGF in the two groups were lower than before treatment, and the observation group was lower than the control group (P<0.05). The scores in the observation group were higher than those in the control group (P<0.05). Conclusion Kanglaite injection combined with GP chemotherapy regimen can effectively reduce the level of VEGF in patients with NSCLC and improve the quality of life of patients.
作者
陈海龙
谢传华
潘宜云
郭守俊
黄萍
邱伊连
CHEN Hailong;XIE Chuanhua;PAN Yiyun;GUO Shoujun;HUANG Ping;QIU Yilian(Ganzhou Cancer Hospital,Ganzhou Jiangxi 341000,China)
出处
《药品评价》
CAS
2023年第1期78-80,共3页
Drug Evaluation
关键词
非小细胞肺癌
康莱特注射液
GP化疗方案
血管内皮生长因子
生存质量
Non-small cell lung cancer
Kanglaite injection
GP chemotherapy regimen
Vascular endothelial growth factor
Quality of life
